Bukwang Pharm. announced that it received IND approval for the Phase 2a clinical trial in South Africa of JM-010, its candidate for levodopa-induced dyskinesia (LID), originally developed by Contera Pharma now Bukwang’s wholly-owned subsidiary in Denmark. LID is a movement disorder that occurs due to levodopa in Parkinson’s disease patients.
Bukwang’s representative said, “LID is an inevitable side effect of levodopa that 60~70% of Parkinson’s disease patients experience after a long-term administration of levodopa for treatment of Parkinson’s. JM-010 is a new agent targeting LID and we are planning to complete the clinical trial in South Africa by early next year.”
Bukwang has recently been reinforcing its R&D for innovative drug development, conducting clinical trials for apatinib mesylate (targeted anti-cancer agent) and MLR-1023 (anti-diabetic agent).
“We are going to expand our efforts in establishing the company’s future growth engine in the overseas market by innovative R&D rather than in the domestic market,” Bukwang’s representative said.